Management of the Idiopathic Overactive Bladder With Botulinum Toxin: Systematic Review

Study Overview
=================
Brief Summary
-----------------
Overactive bladder is defined as a syndrome composed of urgency, increased urinary frequency, and sometimes urinary incontinence; its etiology may be characterized as neurogenic or non-neurogenic (i.e., idiopathic). This illness has a great impact in quality of life and one of the available treatments is the injection of Botulinum Toxin. This study aims to review the efficacy and safety of type-A Botulinum Toxin in the management of Idiopathic Overactive Bladder. A systematic search was performed in MEDLINE, EMBASE, CENTRAL and LILACS, and the controlled randomized clinical trials were chosen to review with the CONSORT criteria by independent reviewers. Outcomes analyzed were the efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence), adverse events to treatment, change in quality of life and urodynamic measures.

Official Title
-----------------
Management of the Idiopathic Overactive Bladder With Intradetrusor Injection of Type-A Botulinum Toxin: Systematic Review of the Literature

Conditions
-----------------
Urinary Bladder, Overactive

Intervention / Treatment
-----------------
* Drug: Intradetrusor Injection of Type-A Botulinum Toxin
* Other: Other interventions analyzed according to protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Controlled randomized clinical trials Adult patients diagnosed with idiopathic overactive bladder Language of the study: english Exclusion Criteria: Diagnosis of neurogenic overactive bladder Patients under 18 years old Use of Type-B Botulinum Toxin as the intervention Other types of studies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Intervention Group<br> | Drug: Intradetrusor Injection of Type-A Botulinum Toxin<br> <br> |
| Control Group<br> | Other: Other interventions analyzed according to protocol<br>* Placebo Different dosage of Type-A Botulinum Toxin injected Anticholinergic drugs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence) |  | Minimun follow-up period of 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events to treatment (urinary retention and urinary tract infections) |  | Minimun follow-up period of 12 weeks | 
| Change in quality of life |  | Minimun follow-up period of 12 weeks | 
| Change in urodynamic measures | Increase in maximum cystometric capacity, first desire to void, normal desire to void, postvoid residual volume, and the presence/abscence of detrusor overactivity. | Minimun follow-up period of 12 weeks |